<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552795</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20200396H</org_study_id>
    <nct_id>NCT04552795</nct_id>
  </id_info>
  <brief_title>Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease</brief_title>
  <acronym>ART-AD</acronym>
  <official_title>Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bess Frost, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Owens Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine&#xD;
      (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress&#xD;
      neurodegeneration, and assess safety and tolerability in patients with early stage&#xD;
      Alzheimer's disease. This study will provide the initial data on target engagement and&#xD;
      Alzheimer's disease-relevant outcomes for future trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label study of 3TC will collect initial proof-of-concept data on 3TC target&#xD;
      engagement, CNS penetration, efficacy and safety in older adults with early stage Alzheimer's&#xD;
      disease. If successful, data will be used to design a larger phase 2 clinical trial. The&#xD;
      investigators aim to I) Quantify 3TC target engagement and CNS penetration, II) Determine if&#xD;
      3TC suppresses Alzheimer's disease-relevant outcomes, and III) Assess the safety and&#xD;
      tolerability of 3TC in older individuals with early Alzheimer's disease. The study will&#xD;
      consist of a screening/baseline period of 30 days pre-treatment, a 24-week open label&#xD;
      treatment period, and a follow up visit one month following treatment. Visits to the clinic&#xD;
      include a pre-treatment screening visit that includes a comprehensive neuropsychological&#xD;
      exam, a tablet-based neuropsychological exam, and a blood draw. For eligible participants, a&#xD;
      lumbar puncture will be performed on day one of treatment. Participants will visit the clinic&#xD;
      on day one of treatment and at weeks 8, 16, and 24 of treatment to complete medication&#xD;
      checks, physical examinations, tablet-based cognitive screening, and blood draw. At week 24&#xD;
      of treatment, patients will undergo a post-treatment comprehensive neuropsychological exam, a&#xD;
      lumbar puncture to collect cerebrospinal fluid, and a blood draw. One month after the final&#xD;
      dose of medication, participants will return to the clinic for a final safety assessment and&#xD;
      disenrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, one arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in reverse transcriptase activity from baseline to 24 weeks in blood and cerebrospinal fluid (CSF) of study participants</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The extent of 3TC target engagement will be measured by calculating the change in reverse transcriptase activity in plasma and CSF of participants at baseline compared to week 24 using a modified version of the EnzCheck Reverse Transcriptase Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3TC CNS penetration in participants</measure>
    <time_frame>24 weeks</time_frame>
    <description>The extent of 3TC CNS penetration will be calculated based on the ratio of plasma to CSF levels of 3TC 5'-triphosphate using High Performance Liquid Chromatography with tandem Mass Spectrometry (HPLC/MS/MS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dementia severity from baseline to week 24 of treatment based on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The CDR-SOB is a semi-structured interview with both subjects and caregivers, scored on six domains of cognitive functioning: memory, orientation, judgment, community affairs, home and hobbies, and personal scale. The CDR-SOB is obtained by summing each of the domains, with scores ranging from 0-18. Higher scores denote greater dementia severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Baseline, Week 8, Week 16, Week 24</time_frame>
    <description>Incidence of adverse and serious adverse events likely due to study drug will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal vital signs</measure>
    <time_frame>Baseline, Week 8, Week 16, Week 24</time_frame>
    <description>Vital signs including blood pressure, heart rate, temperature, and respiration will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal laboratory test results</measure>
    <time_frame>Baseline, Week 8, Week 16, Week 24</time_frame>
    <description>A complete blood count (CBC) and comprehensive metabolic panel (CMP) will be measured.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alzheimer Disease, Early Onset</condition>
  <arm_group>
    <arm_group_label>Open-Label 3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive 3TC, 300-mg, daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC</intervention_name>
    <description>12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.</description>
    <arm_group_label>Open-Label 3TC</arm_group_label>
    <other_name>Epivir</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 50-99 years&#xD;
&#xD;
          2. Clinical diagnosis of early Alzheimer's disease (Clinical Dementia Rating (CDR) = 0.5,&#xD;
             Mini-Mental State Exam (MMSE) = 24-30)&#xD;
&#xD;
          3. If using drugs to treat symptoms related to Alzheimer's disease, doses must be stable&#xD;
             for at least eight weeks prior to screening visit 1&#xD;
&#xD;
          4. Labs: Adequate blood cell counts (white blood cells: 4,000-111,000 cells per&#xD;
             microliter (cells/mcL); absolute neutrophil count: 1,800-8,700 cells/mcL; platelets:&#xD;
             120-500 K/µL; hemoglobin 12.0-17.5 grams/dL); LFT's within 2x normal value; creatinine&#xD;
             clearance test (CrCl) ≥ 50 mL/min; cholesterol (≤260 mg/dl), triglycerides≤ 400&#xD;
             mg/dl), and glucose control (HbA1c ≤ 8%). Prothrombin time/partial thromboplastin&#xD;
             time/international normalized ratio (PT/PTT/INR) within normal limits&#xD;
&#xD;
          5. Body mass index (BMI) within range of 19 - 35 kg/m2&#xD;
&#xD;
          6. Must have a reliable informant or caregiver&#xD;
&#xD;
          7. Participants must have no plans to travel that interfere with study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any medical or neurologic condition (other than Alzheimer's Disease) that might be a&#xD;
             contributing cause of the subject's cognitive impairment&#xD;
&#xD;
          2. Clinically significant unstable psychiatric illness in the past six months&#xD;
&#xD;
          3. Significant hearing, vision, or motor deficits that interfere with participation&#xD;
&#xD;
          4. Alcohol or drug abuse/dependence in the past six months&#xD;
&#xD;
          5. Stroke, transient ischemic attack, or unexplained loss of consciousness in the past&#xD;
             six months&#xD;
&#xD;
          6. Unstable angina, myocardial infarction, advanced chronic heart failure, or clinically&#xD;
             significant conduction abnormalities within the past six months&#xD;
&#xD;
          7. Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities&#xD;
&#xD;
          8. Diagnosis of HIV infection or AIDS (CD4 count &lt; 200), HIV/Hepatitis B Virus (HBV)&#xD;
             co-infection, HBV or human T-cell leukemia virus infection&#xD;
&#xD;
          9. History of impaired renal or liver function&#xD;
&#xD;
         10. Current use of memantine or sorbitol-containing products&#xD;
&#xD;
         11. Individuals with HIV, HBV, or who have current/previous use of Nucleoside Reverse&#xD;
             Transcriptase Inhibitors (NRTIs) or non-NRTIs.&#xD;
&#xD;
         12. Poorly controlled blood pressure (BP) (systolic BP &gt; 160, diastolic BP &gt; 90 mmHg)&#xD;
&#xD;
         13. Uncontrolled diabetes (HbA1c &gt; 8%, or the current use of insulin)&#xD;
&#xD;
         14. Significant systematic illness or infection in the past 30 days&#xD;
&#xD;
         15. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Frost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bess Frost, PhD</last_name>
    <phone>(210) 562-5037</phone>
    <email>bfrost@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoinette Lewis, MPA</last_name>
    <phone>(210) 450-8023</phone>
    <email>lewisa7@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bess Frost, PhD</last_name>
      <phone>210-562-5037</phone>
      <email>bfrost@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Bess Frost, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Campbell Sullivan, PsyD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sam and Ann Barshop Institute for Longevity &amp; Aging Studies</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bess Frost, PhD</last_name>
      <phone>210-562-5037</phone>
      <email>bfrost@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antoinette Lewis, MPA</last_name>
      <phone>210-450-8023</phone>
      <email>lewisa7@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bess Frost, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Musi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bess Frost, PhD</last_name>
      <phone>210-562-5037</phone>
      <email>bfrost@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antoinette Lewis, MPA</last_name>
      <phone>210-450-8023</phone>
      <email>lewisa7@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bess Frost, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Campbell Sullivan, PsyD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Musi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 6, 2022</last_update_submitted>
  <last_update_submitted_qc>April 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Bess Frost, PhD</investigator_full_name>
    <investigator_title>Associate Professor, Sam and Ann Barshop Instititute for Aging and Longevity Studies, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Disorders, Department of Cell Systems and Anatomy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Protocol, Published Data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After study completion, upon publication of data and on ClinicalTrials.gov 1 year after primary completion date of study.</ipd_time_frame>
    <ipd_access_criteria>Data will be analyzed by the study investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

